SCHEMBL16617787

SCHEMBL16617787

CC(C)(C)C(=O)NC(C(=O)C1CCCCC1C(=O)O)c1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
ANPEP P15144 1/20 0.40
GRK2 P25098 1/20 0.38
CASP6 P55212 1/20 0.38
CASP8 Q14790 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CYP1A2 P05177 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FPR2 P25090 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16617326 0.88 POLB (0.41) POLBANPEPALDH1A1CYP3A4CYP2C9
SCHEMBL16618154 0.75 TAS1R3 (0.41) ANPEPGRK2CASP6CASP8CTDSP1
SCHEMBL16617722 0.74 HSD11B1 (0.39) POLBGRK2CASP6CASP8CTDSP1
SCHEMBL16617692 0.73 GRK2 (0.42) POLBGRK2CASP6CASP8CTDSP1
SCHEMBL16617582 0.73 CYP2C19 (0.38) POLBGRK2CASP6CASP8CTDSP1
Hydrochloric Acid SCHEMBL16618172 0.72 GRK2 (0.41) POLBGRK2CASP6CASP8CTDSP1
SCHEMBL16646026 0.71 POLB (0.43) POLBALDH1A1CYP3A4TSHRHTT
SCHEMBL16617954 0.68 GRK2 (0.38) POLBGRK2CASP6CASP8CTDSP1
SCHEMBL16617817 0.68 CYP3A4 (0.48) POLBANPEPALDH1A1CYP3A4CYP2C9
SCHEMBL16617819 0.68 CYP3A4 (0.48) POLBANPEPALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
EP-3055314-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ POLB 3196/4885ANPEP 89/4885GRK2 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.